US FDA Sees Leqembi Data As Vindicating Its Approach To Alzheimer’s Drugs

 
• By Brenda Sandburg
Alzheimer's puzzle
FDA touts confidence in connection between amyloid placque reduction and reduction in clinical decline • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers